PROBLEM TO BE SOLVED: To avoid the adverse effect of NSAIA by increasing the dissolubility thereof in gastric juice and by achieving an increase in permeability thereof through the membrane and skin barrier which would make them percutaneous-administration possible (topical application).SOLUTION: We have synthesized a novel positively charged prodrug of aryl- as well as heteroaryl-propionic acid represented by formula (1) and formula (2). Said prodrug diffuses through human skin about 100 to 130-folds faster than the parent drug thereof. When said prodrugs are percutaneously administered, they reach the peak plasma level in just about 40 to 50 minutes. The prodrug can pharmaceutically be used not only in oral administration but also in transdermal administration for the treatment of NSAIA-treatable condition in humans or animals, and the most adverse effects of NSAIA can be avoided.SELECTED DRAWING: Figure 17
